.Attribute Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint calls for introduction of individuals with MASLD and also measurement of liver end results in cardio-- renal-- metabolic trials, when data recommend mechanistically probable benefits and medical protection-- and also details factors for trial design and also regulatory approval.